Acadia’s 50-day moving average is in the process of crossing above the stock’s 200-day moving average. This crossover forms a ...

Guggenheim has recently reduced ACADIA Pharmaceuticals Inc (ACAD) stock to Neutral rating, as announced on January 3, 2025, according to Finviz. Earlier, on October 10, 2024, Raymond James had resumed ...

Fintel reports that on January 3, 2025, Guggenheim downgraded their outlook for ACADIA Pharmaceuticals (NasdaqGS:ACAD) from ...

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $18.66, but opened at $18.25. ACADIA ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating ...

As previously reported, Guggenheim downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a price target of $20, down from $23. The ...

ACADIA Pharmaceuticals Inc (ACAD) stock saw a modest uptick, ending the day at $18.35 which represents a slight increase of $1.66 or 9.95% from the prior close of $16.69. The stock opened at $18.24 ...

Acadia Pharmaceuticals will replace Independent Bank Group in S&P SmallCap 600, effective prior to opening of trading on Jan.

Shares of Acadia Pharmaceuticals rose after the company said it was set to join the S&P SmallCap 600 index. The biopharmaceutical company's stock jumped 12% to $18.73 in morning trading Tuesday, ...

Acadia Pharmaceuticals (ACAD) will replace Independent Bank Group (IBTX) in the S&P SmallCap 600 effective prior to the opening of trading ...

In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted ...